The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00611416 |
Recruitment Status
:
Completed
First Posted
: February 8, 2008
Last Update Posted
: February 9, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity | Dietary Supplement: green tea Dietary Supplement: Mix of catechins and caffeine Dietary Supplement: EGCG Dietary Supplement: EGC Dietary Supplement: Caffeine Dietary Supplement: Placebo | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 15 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism in Man |
Study Start Date : | November 2005 |
Actual Study Completion Date : | February 2006 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Active treatment A
|
Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: Mix of catechins and caffeine
3 tablet a day
|
Experimental: 2
Active treatment B
|
Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: EGCG
3 tablets a day
Other Name: epigallocatechin gallate
|
Experimental: 3
Active treatment C
|
Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: EGC
3 tablets a day
Other Name: Epigallocatechin
|
Active Comparator: 4
Positive control
|
Dietary Supplement: Caffeine
3 tablets a day
|
Placebo Comparator: 5
Placebo
|
Dietary Supplement: Placebo
3 tablets a day
|
- fat oxidation [ Time Frame: november 2007 ]
- appetite [ Time Frame: november 2007 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy men
- Age 18-40 years
- BMI 18,5-25 kg/m2
Exclusion Criteria:
- Diabetes or any other endocrinological disease
- Hypertensive medication
- Increased Blood Pressure > 140/85
- Hyperlpidimia
- Chronic disease (i.e. HIV)
- Use of any diet supplements including vitamins (during and 3 months prior to the study).
- High alcohol intake (>21 units a week)
- High caffeine intake (>250 mg/day) or high catechin intake (>200 mg/day)
- Smoking
- Elite sports performer
- Use of any regular medication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00611416
Denmark | |
Institute of Human Nutrition, The Royal Veterinary and Agricultrual University | |
Frederiksberg C, Denmark, 1958 |
Study Chair: | Arne Astrup, Proffessor | Insitute of Human Nutrition |
ClinicalTrials.gov Identifier: | NCT00611416 History of Changes |
Other Study ID Numbers: |
(KF) 01 279421 Unilever |
First Posted: | February 8, 2008 Key Record Dates |
Last Update Posted: | February 9, 2009 |
Last Verified: | February 2009 |
Keywords provided by University of Copenhagen:
catechins caffeine energy expenditure fat oxidation appetite |
Additional relevant MeSH terms:
Caffeine Epigallocatechin gallate Central Nervous System Stimulants Physiological Effects of Drugs Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists |
Purinergic Agents Neurotransmitter Agents Antioxidants Protective Agents Antimutagenic Agents Anticarcinogenic Agents Antineoplastic Agents Neuroprotective Agents |